While antiangiogenic therapy made a splash in the 1990s with its success
in eradicating cancerous tumors in mice, the agents, when used alone, have
fared poorly in the clinic. It seems that the drugs’ ability to block
formation of new blood vessels to bring oxygen and nutrients to tumors is
not enough to combat established tumors in humans.
Looking back, this therapeutic failure is not surprising, says chemical
engineer-turned-tumor biologist Rakesh K. Jain, PhD, of the Massachusetts
General Hospital, in Boston. An antiangiogenic agent “can kill many
to most cancer cells, but the remaining cancer cells will begin to make new
angiogenic molecules and new blood vessels will come up again,” he said.
Hampton T. Antiangiogenic Therapy a Two-Trick Pony?. JAMA. 2005;293(9):1051. doi:10.1001/jama.293.9.1051